Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Brown, Jennifer
Item TypeName
Academic Article Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Concept Protein Kinase Inhibitors
Academic Article Novel agents for the treatment of chronic lymphocytic leukemia.
Academic Article Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition.
Academic Article Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Academic Article A new era of treatment for chronic lymphocytic leukaemia?
Academic Article Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
Academic Article Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Academic Article Idelalisib for chronic lymphocytic leukemia.
Academic Article Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Academic Article Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
Academic Article Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Academic Article Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.
Academic Article Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances.
Academic Article Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies.
Academic Article Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Academic Article Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Academic Article Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Academic Article Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
Academic Article How I treat CLL patients with ibrutinib.
Academic Article Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Academic Article Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Academic Article Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Academic Article Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Academic Article Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.